Impact of Adherence to Treatment in Asthma Control

• Analyze how adherence to treatment using ASK-20 questionnaire and prescription account influences level of asthma control in a sample of patients with severe and moderate-mild asthma. [ Time Frame: 4 weeks ] [ Designated as safety issue: No ]
  To analyze how adherence to treatment using ASK-20 questionnaire and prescription account influences level of asthma control in a sample of patients with severe and moderate-mild asthma.
  
  

• Analyze the correlation between the level of asthma control according to the Asthma Control Test (ACT) and the Asthma Control Questionnaire (ACQ) scores and the fraction exhaled of nitric oxide (FeNO) [ Time Frame: 4 weeks ] [ Designated as safety issue: No ]
  
• Analyze the correlation between the level of asthma control according to the ACT and the ACQ scores and the gender [ Time Frame: 4 weeks ] [ Designated as safety issue: No ]
  
• Analyze the correlation between the level of asthma control according to the ACT and the ACQ scores and smoking habit [ Time Frame: 4 weeks ] [ Designated as safety issue: No ]
  
• Analyze the correlation between the level of asthma control according to the ACT and the ACQ scores and obesity [ Time Frame: 4 weeks ] [ Designated as safety issue: No ]
  
• Analyze the correlation between the level of asthma control according to the ACT and the ACQ scores and concomitant diseases (rhinitis, sinusitis or gastroesophageal reflux) [ Time Frame: 4 weeks ] [ Designated as safety issue: No ]
  
• Analyze the correlation between the level of asthma control according to the ACT and the ACQ scores and concomitant psychiatric disorders [ Time Frame: 4 weeks ] [ Designated as safety issue: No ]
  
• Analyze the most relevant differences in the study population [ Time Frame: 4 weeks ] [ Designated as safety issue: No ]
  

Duration of illness, poor adherence to treatment, gender, smoking habit, obesity, concomitant diseases (rhinitis, sinusitis or gastroesophageal reflux) and concomitant psychiatric disorders may be responsible for an increase and perpetuation of the inflammatory response as well as a decreased response to treatment and may be easily identified clinically.

PRIMARY OBJECTIVES: a) To analyze how adherence to treatment influences level of asthma control in a sample of patients with severe and moderate-mild asthma.

SECONDARY OBJECTIVES: a) To analyze the correlation between the level of asthma control according to the Asthma Control Test (ACT) and the Asthma Control Questionnaire (ACQ) scores and the fraction exhaled of nitric oxide (FeNO); b) To analyze the correlation between the level of asthma control according to the ACT and the ACQ scores and the gender. c) To analyze the correlation between the level of asthma control according to the ACT and the ACQ scores and smoking habit. d) To analyze the correlation between the level of asthma control according to the ACT and the ACQ scores and obesity. e) To analyze the correlation between the level of asthma control according to the ACT and the ACQ scores and concomitant diseases (rhinitis, sinusitis or gastroesophageal reflux). f) To analyze the correlation between the level of asthma control according to the ACT and the ACQ scores and concomitant psychiatric disorders. g) To analyze the most relevant differences in the study population.

METHOD: This is a observational cross-sectional study that includes a sample made up of 50 patients with severe asthma and 50 patients with mild-moderate asthma according to the Global Initiative for Asthma (GINA).

DEVELOPMENT OF THE STUDY After signing the informed consent, data will be collected including gender, smoking habit, alcohol consumption, environmental and employment factors, weight, height, body mass index (BMI), history of atopy, rhinosinusitis, gastroesophageal reflux and concomitant psychiatric disorders and a standard physical examination. Measurement of asthma control with the ACQ and ACT questionnaires will be performed. Then FeNO measurement and pulmonary function testing (forced spirometry and bronchodilator test) will be performed .

DEVICES AND MEASUREMENTS: Clinical variables will be collected in a CRF(case report form) specially developed for the study. Functional study: The spirometry will be performed according to the recommendations of European Respiratory Society using the Jaëger Master Lab system.

Bronchodilator test will be performed with albuterol and ipratropium bromide inhalation solution. FeNO levels will be measured of using the Filt's Vario analyzer which allows for bronchial or nasal tests, with a Lilly-type pnemo-tacographic flow and volume meter. Adherence to treatment will be assessed with the ASK-20 questionnaire and reviewing the number of prescriptions for asthma during the last 6 months.